Health & Medications

GLP-1 Study Finds Better Liver Outcomes in Older Adults, With Caveats

By Priya Lindqvist / October 30, 2026 / Updated November 8, 2026

A smiling older couple walking together along a city street

A large study of medical records from older adults with fatty liver disease found that people who started a GLP-1 medicine had fewer serious liver complications and fewer deaths than similar people who did not. That is encouraging, but the study looked back at records rather than testing the medicines directly, so it shows a link, not a cause. The treated group also had more diagnoses of osteoporosis and of an eye condition called retinopathy, and no drop in heart attacks or strokes.

Key takeaways

Among 87,860 older adults with fatty liver disease, those who started a GLP-1 medicine had lower rates of serious liver complications and of death.
The study was observational. It cannot show the medicines caused the lower rates, as the authors say.
Osteoporosis (without a broken bone) and retinopathy were diagnosed more often in the treated group. Heart attacks and strokes were not reduced.
A separate randomized trial of one GLP-1 medicine studied a more advanced form of the disease, so it does not settle the question for older adults.
Whether any of this applies to you is a question for your doctor.

What the researchers studied

A team at the Houston Methodist Research Institute in Texas led the work. It appeared in the journal Age and Ageing (volume 55, issue 9), which lists an online publication date of 21 September 2026. Houston Methodist issued a press release on 13 October 2026.

Three terms, explained once:

GLP-1 medicines are a group of drugs, named after a hormone called glucagon-like peptide-1, used for blood sugar control and weight loss. Semaglutide was prescribed most often in this study, followed by tirzepatide and dulaglutide.
MASLD means metabolic dysfunction-associated steatotic liver disease: extra fat in the liver, linked to conditions such as obesity or type 2 diabetes.
Hepatic decompensation is a serious step in liver disease, when the liver can no longer cope and complications appear.

The researchers used TriNetX, a U.S. database of health records from 69 healthcare organizations. Before matching, 44,196 adults aged 65 or older with MASLD had started a GLP-1 medicine and 384,672 had not. The team then paired people with similar ages, health conditions, medicines and lab values, giving two matched groups of 43,930 each. The average age was 71.8, and 62% were women. Follow-up ran from 90 days to 10 years.

What they found

The benefits

The press release reports a 28% lower risk of serious liver deterioration and a 45% lower risk of death from any cause in the treated group. The journal abstract gives hazard ratios, which compare how often something happens over time in two groups. A value of 1.0 means no difference. Below 1.0 means fewer events in the treated group.

Outcome	Hazard ratio (95% confidence range)	What it suggests
Hepatic decompensation	0.72 (0.66 to 0.79)	Lower rate in the treated group
Death from any cause	0.55 (0.52 to 0.58)	Lower rate in the treated group
Hospitalization	0.95 (0.93 to 0.97)	Slightly lower rate
Major heart events (heart attack, stroke and related events)	0.98 (0.92 to 1.04)	No clear difference
Osteoporosis without a fracture; retinopathy	Not given in the abstract	Diagnosed more often in the treated group
Fractures, muscle loss, pancreatitis	Not given in the abstract	No clear difference

The liver and death results held up when the researchers changed how follow-up time was counted. They also held up with tirzepatide left out, where the hazard ratios were 0.68 for death and 0.83 for decompensation, according to Managed Healthcare Executive. The lower liver risk also appeared across groups defined by diabetes status and body weight.

The warning signals

Osteoporosis diagnosed without a broken bone, and retinopathy, were recorded more often in the treated group. Stomach and bowel problems were also more often the first event for treated people. The study cannot say why. One trade report notes that more diagnoses might partly reflect closer medical monitoring, but that is a possibility, not a finding. Long-term safety was not assessed.

The main analysis showed no reduction in heart attacks or strokes. A small one (hazard ratio 0.89) appeared only in an alternative analysis that began counting on day one, so read it cautiously.

Why “linked to” does not mean “caused by”

The researchers matched the groups carefully, but matching can only balance what is written in the files. A person who is offered and able to start a new medicine may differ in ways the records miss, such as general frailty or how easily they get care. These hidden differences, called residual confounding, could explain part of the result.

The authors say the findings do not prove that treatment caused the lower risks. First author Tilemachos Koutouratsas said randomized trials in older adults may be needed to confirm them and to learn who benefits and who needs closer monitoring. In a randomized trial, chance decides who gets the medicine, which removes most hidden differences. These percentages compare groups. They do not tell any one person what to expect.

Where things stand as of 8 November 2026

In the weeks since the first reports, our searches found no new randomized trial or new guideline aimed at older adults with MASLD. U.S. Pharmacist adds that frailty, muscle loss, several health conditions and many medicines are common in older adults with this disease, and can affect survival on their own.

The wider picture comes from a different group of patients. In April 2025 the New England Journal of Medicine published part of the ESSENCE trial of semaglutide 2.4 mg in people with MASH (a more advanced form of fatty liver disease, once called NASH) with moderate to advanced scarring. King’s College London reports that 800 adults were analyzed at 72 weeks. Liver inflammation improved in 62.9% on the medicine versus 34.3% on placebo, and scarring improved in 36.8% versus 22.4%. The manufacturer funded the trial, and long-term follow-up continues.

In August 2025 the U.S. Food and Drug Administration approved Wegovy (semaglutide 2.4 mg) for adults with MASH and moderate to advanced scarring but not cirrhosis, as reported by HCPLive. The approval rests on those 72-week liver tissue results, and a longer part of the trial, on liver-related clinical events, continues. In November 2025 the American Association for the Study of Liver Diseases published updated guidance in Hepatology on semaglutide for that group. None of this is the same as the Houston Methodist study, which covered people aged 65 and older and relied on records.

Questions to bring to your doctor

This list is for starting a conversation. It is not advice to start or stop any medicine.

What stage is my liver disease, and how was that measured?
Is a GLP-1 medicine worth considering in my situation, and what are the alternatives?
How should my bones, eyes and heart be checked if I take one?
What side effects should I watch for, and whom do I call?
When should I be rechecked, and which results matter most?

Frequently asked questions

Does this study prove GLP-1 medicines protect the liver in older people?

No. Treated people had lower rates of serious liver problems and death, but this was a records review. Differences the records missed could explain part of the gap.

Why were osteoporosis and retinopathy more common in the treated group?

The study does not say. It could be a side effect, closer monitoring, or a difference the records missed. These are diagnoses, not proven harms.

Is a GLP-1 medicine approved for fatty liver disease?

The FDA approved Wegovy in August 2025 for adults with MASH, with moderate to advanced scarring but not cirrhosis. That is a narrower group than the people in this study. Whether a medicine suits you is for you and your doctor to decide.

Should I ask my doctor about this?

If you have fatty liver disease or risk factors for it, raising the topic is reasonable. Your doctor can explain how your own results and medicines affect the choices.

Before you decide

This study is large and points in a hopeful direction for the liver. It also raised questions about bones and eyes, and it showed no heart benefit. Treat the headline figures as a reason to ask informed questions, not to change what you take. Please do not start, stop or change any prescription because of a news story. Your doctor or pharmacist can look at your complete picture.